Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.0168
Abstract: Importance Pancreatic cancer is the third most common cause of cancer death; however, randomized clinical trials (RCTs) of survival in patients with resectable pancreatic cancer lack mandatory measures for reporting baseline and prognostic factors, which… read more here.
Keywords: prognostic factors; consensus; resectable borderline; pancreatic cancer ... See more keywords
Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5523
Abstract: There is no agreed upon standard of care for borderline‐resectable pancreatic cancer (BRPC) or locally‐advanced pancreatic cancer (LAPC) patients regarding the benefit of chemotherapy or radiation alone or in combination. read more here.
Keywords: locally advanced; neoadjuvant chemotherapy; pancreatic cancer; borderline resectable ... See more keywords
Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5971
Abstract: BACKGROUND Neoadjuvant treatment with nab-paclitaxel and gemcitabine for potentially operable pancreatic adenocarcinoma has not been well studied in a prospective interventional trial and could down-stage tumors to achieve negative surgical margins. METHODS A single-arm, open-label… read more here.
Keywords: node positive; nab paclitaxel; borderline resectable; gemcitabine ... See more keywords
A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of hepato-biliary-pancreatic sciences"
DOI: 10.1002/jhbp.1026
Abstract: BACKGROUND We advocated carbohydrate antigen (CA) 19-9 ≥ 150 U/mL and tumor size ≥ 30 mm as "high-risk markers" for predicting unresectability among patients with radiologically resectable (R) or borderline resectable (BR) pancreatic ductal adenocarcinoma… read more here.
Keywords: risk markers; risk; resectable borderline; high risk ... See more keywords
Long-term outcome following neoadjuvant therapy for resectable and borderline resectable pancreatic cancer compared to upfront surgery: a meta-analysis of comparative studies by intention-to-treat analysis
Sign Up to like & getrecommendations! Published in 2019 at "Surgery Today"
DOI: 10.1007/s00595-019-01786-w
Abstract: The aim of the study was to evaluate the effect of neoadjuvant therapy on long-term survival in patients with resectable and borderline resectable pancreatic cancer. A meta-analysis was conducted using the reported randomized, controlled trials… read more here.
Keywords: resectable borderline; long term; analysis; resectable pancreatic ... See more keywords
Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Gastrointestinal Cancer"
DOI: 10.1007/s12029-020-00417-9
Abstract: Background Patients with borderline resectable pancreatic cancer are at high risk of incomplete resection with upfront surgery. Currently, no standard induction chemotherapy regimen exists for these patients. Both FOLFIRINOX (5-FU, irinotecan, & oxaliplatin) and gemcitabine… read more here.
Keywords: patients borderline; folfirinox gnp; resectable pancreatic; pancreatic cancer ... See more keywords
Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Colorectal Cancer"
DOI: 10.1016/j.clcc.2016.09.007
Abstract: Background: For borderline resectable colorectal cancer liver metastases (CLM), systemic treatment can help to achieve R0 resection and reduce the risk of relapse. We assessed the role of perioperative triplet chemotherapy in combination with cetuximab… read more here.
Keywords: risk; ras wild; colorectal cancer; borderline resectable ... See more keywords
A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of cancer"
DOI: 10.1016/j.ejca.2021.10.012
Abstract: BACKGROUND The prognosis of patients with borderline resectable pancreatic cancer with arterial contact (BRPC-A) is extremely poor, and effective preoperative treatment is indispensable. We evaluated the clinical efficacy and safety of neoadjuvant chemotherapy, including gemcitabine,… read more here.
Keywords: chemotherapy; patients borderline; nab paclitaxel; study ... See more keywords
Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery
Sign Up to like & getrecommendations! Published in 2021 at "Acta Oncologica"
DOI: 10.1080/0284186x.2021.1944662
Abstract: Abstract Background Neoadjuvant treatment (NAT) is debated for borderline resectable pancreatic cancer (BRPC). This retrospective study assessed the impact of NAT on R0 rate and survival for BRPC patients in comparison with upfront surgery (US).… read more here.
Keywords: rfs; resectable pancreatic; rate; borderline resectable ... See more keywords
How to treat borderline resectable pancreatic cancer: current challenges and future directions
Sign Up to like & getrecommendations! Published in 2018 at "Japanese Journal of Clinical Oncology"
DOI: 10.1093/jjco/hyx191
Abstract: Borderline resectable pancreatic cancer (BRPC) is an advanced tumor in contact with the surrounding major vessels, making R0 resection difficult to achieve. Neoadjuvant treatment is expected to provide substantial local control and prolong survival. However,… read more here.
Keywords: treatment; resectable pancreatic; pancreatic cancer; borderline resectable ... See more keywords
Abstract B34: The impact of lymphocyte-to-monocyte ratio (LMR) in patients with borderline resectable pancreatic head cancer after curative surgery
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Research"
DOI: 10.1158/1538-7445.panca19-b34
Abstract: Introduction: The outcome of patients with borderline resectable pancreatic ductal adenocarcinoma (BR PDAC) remains dismal even if the patients received neoadjuvant chemotherapy followed by radical resection. Pancreatic resection is highly invasive and sometimes fatal; thus,… read more here.
Keywords: lymphocyte; lmr; cancer; monocyte ... See more keywords